RSV-INDUCED PATTERNS OF CYTOKINE EXPRESSION AND DISEASE

RSV 诱导的细胞因子表达模式和疾病

基本信息

  • 批准号:
    2330385
  • 负责人:
  • 金额:
    $ 22.26万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1994
  • 资助国家:
    美国
  • 起止时间:
    1994-02-01 至 1999-01-31
  • 项目状态:
    已结题

项目摘要

Respiratory syncytial virus (RSV) is an important cause of respiratory disease that has received high priority for vaccine development. Previous vaccine candidates have failed in clinical trials, and formalin- inactivated alum-precipitated whole virus preparation was associated with vaccine-enhanced illness. RSV subunit vaccines are in preclinical development and early phase I trials in RSV-seropositive infants have begun. We have described a BALB/c mouse model for the study of RSV immunopathogenesis, and have recently obtained evidence that priming with inactivated RSV antigen induces a type 2T helper lymphocyte (Th2) pattern of cytokine mRNA expression (dominant IL-4 expression), whereas priming with live RSV induces a Th1-like response (dominant IFN-gamma expression) in mice following RSV challenge. Finding that initial antigen priming can result in selective induction of immune responses following subsequent nasal challenge, suggests a new and testable hypothesis for the pathogenesis of RSV-vaccine enhance illness. There is evidence in other animal model systems that selective activation of Th subsets can be induced by immunization or infection and can influence disease outcome. It has recently been shown that Th immunization or infection and can influence disease outcome. It has recently been shown that Th lymphocyte subpopulations with distinct patterns of cytokine secretion can also be found in man. We therefore propose to utilize the mouse model of RSV to determine the mechanism by which immunization selectively activate T cell populations and patterns of cytokine expression. We will identify the phenotype of cells that produce the cytokine mRNA in lung. We will also define the correlation between formulation, route, dose, and timing of priming immunization and the pattern of cytokine mRNA expression in lung and expression of disease. This work will add to our general understanding of the immunologic determinants of RSV vaccine- enhanced disease can be identified will advance vaccine development for RSV and other surface-restricted viruses.
呼吸道合胞病毒(RSV)是引起呼吸道疾病的重要原因

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

BARNEY S GRAHAM其他文献

BARNEY S GRAHAM的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('BARNEY S GRAHAM', 18)}}的其他基金

CANARYPOX ALVAC HIV VACCINES IN HIV 1 UNINFECTED ADULT VOLUNTEERS
1 名未感染 HIV 的成年志愿者中使用金丝雀痘 ALVAC HIV 疫苗
  • 批准号:
    6305716
  • 财政年份:
    1999
  • 资助金额:
    $ 22.26万
  • 项目类别:
EVALUATE TWO VACCINES IN HEALTHY HIV 1 UNINFECTED ADULTS
在健康 HIV 1 未感染成年人中评估两种疫苗
  • 批准号:
    6305724
  • 财政年份:
    1999
  • 资助金额:
    $ 22.26万
  • 项目类别:
RESPIRATORY SYNCYTIAL VIRUS ON ALLERGIC AIRWAY DISEASE
呼吸道合胞病毒对气道过敏性疾病的影响
  • 批准号:
    2878887
  • 财政年份:
    1999
  • 资助金额:
    $ 22.26万
  • 项目类别:
THERION RECOMBINANT VACCINIA HIV1 IIIB ENV/GAG/POL VACCINE AND MN RGP120/HIV1
THERION 重组疫苗 HIV1 IIIB ENV/GAG/POL 疫苗和 MN RGP120/HIV1
  • 批准号:
    6219583
  • 财政年份:
    1998
  • 资助金额:
    $ 22.26万
  • 项目类别:
LIVE RECOMBINANT CANARY POX ALVAC HIV VCP 300 IN HIV UNINFECTED VOLUNTEERS
活体重组金丝雀痘 ALVAC HIV VCP 300 用于未感染 HIV 的志愿者
  • 批准号:
    6115597
  • 财政年份:
    1998
  • 资助金额:
    $ 22.26万
  • 项目类别:
RECOMBINANT SUBUNIT HIV1 ENVELOPE VACCINES SF 2 RGP120 IN MF59 AND MN RGP120
MF59 和 MN RGP120 中的重组亚单位 HIV1 包膜疫苗 SF 2 RGP120
  • 批准号:
    6219495
  • 财政年份:
    1998
  • 资助金额:
    $ 22.26万
  • 项目类别:
ALVAC HIV VCP205 DELIVERED BY ALTERNATE MUCOSAL ROUTES WITH BOOSTING HIV1 SF2
ALVAC HIV VCP205 通过替代粘膜途径输送,增强 HIV1 SF2
  • 批准号:
    6219580
  • 财政年份:
    1998
  • 资助金额:
    $ 22.26万
  • 项目类别:
EVALUATE TWO VACCINES IN HEALTHY HIV 1 UNINFECTED ADULTS
在健康 HIV 1 未感染成年人中评估两种疫苗
  • 批准号:
    6264589
  • 财政年份:
    1998
  • 资助金额:
    $ 22.26万
  • 项目类别:
UBI KIV LIPOPEPTIDE VACCINE COMPONENT P3C541B IN HIV 1 SERONEGATIVE SUBJECTS
HIV 1 血清阴性受试者中的 UBI KIV 脂肽疫苗成分 P3C541B
  • 批准号:
    6115594
  • 财政年份:
    1998
  • 资助金额:
    $ 22.26万
  • 项目类别:
HIV1 GAG/POL DNA VACCINE GIVEN IM BY NEEDLE, SYRINGE AND BIOJECTOR 2000
HIV1 GAG/POL DNA 疫苗通过针头、注射器和 BIOJECTOR 2000 进行肌内注射
  • 批准号:
    6115670
  • 财政年份:
    1998
  • 资助金额:
    $ 22.26万
  • 项目类别:

相似海外基金

Active immunization mouse model by cN1A peptides
cN1A肽主动免疫小鼠模型
  • 批准号:
    18K15370
  • 财政年份:
    2018
  • 资助金额:
    $ 22.26万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of an efficient oocyte collection method using active immunization against inhibin in cynomolgus monkeys.
使用食蟹猴主动免疫抑制素开发有效的卵母细胞收集方法。
  • 批准号:
    17H06766
  • 财政年份:
    2017
  • 资助金额:
    $ 22.26万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Passive and Active Immunization for Pneumocystis
肺孢子虫的被动和主动免疫
  • 批准号:
    9182862
  • 财政年份:
    2015
  • 资助金额:
    $ 22.26万
  • 项目类别:
Active Immunization for Treating Methamphetamine Abuse
治疗甲基苯丙胺滥用的主动免疫
  • 批准号:
    8136035
  • 财政年份:
    2007
  • 资助金额:
    $ 22.26万
  • 项目类别:
Active Immunization for Treating Methamphetamine Abuse
治疗甲基苯丙胺滥用的主动免疫
  • 批准号:
    7921670
  • 财政年份:
    2007
  • 资助金额:
    $ 22.26万
  • 项目类别:
Can passive or active immunization alter the course of infection with circoviral DNA?
被动或主动免疫可以改变圆环病毒 DNA 的感染过程吗?
  • 批准号:
    306844-2004
  • 财政年份:
    2007
  • 资助金额:
    $ 22.26万
  • 项目类别:
    Special Research Opportunity Program - Project
Active Immunization for Treating Methamphetamine Abuse
治疗甲基苯丙胺滥用的主动免疫
  • 批准号:
    7341002
  • 财政年份:
    2007
  • 资助金额:
    $ 22.26万
  • 项目类别:
Active Immunization for Treating Methamphetamine Abuse
治疗甲基苯丙胺滥用的主动免疫
  • 批准号:
    7502083
  • 财政年份:
    2007
  • 资助金额:
    $ 22.26万
  • 项目类别:
Active Immunization for Treating Methamphetamine Abuse
治疗甲基苯丙胺滥用的主动免疫
  • 批准号:
    7679096
  • 财政年份:
    2007
  • 资助金额:
    $ 22.26万
  • 项目类别:
Passive-Active Immunization Strategies Against Pediatric AIDS
针对儿童艾滋病的被动-主动免疫策略
  • 批准号:
    7065729
  • 财政年份:
    2006
  • 资助金额:
    $ 22.26万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了